Quick Takeaways
- Ikarian Capital, LLC filed SCHEDULE 13G/A for Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX).
- Disclosed ownership: 6.7%.
- Date of event: 31 Mar 2026.
Ikarian Capital, LLC - 31 Mar 2026 SCHEDULE 13G/A Report for Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX)
- Filing Manager
- Ikarian Capital, LLC
- Reporting Manager
- Ikarian Capital, LLC
- Symbol
- TENX
- Shares outstanding
- 17,091,045 shares
- Disclosed Ownership
- 1,145,100 shares
- Ownership
- 6.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 Apr 2026, 21:34:37 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 05 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Ikarian Capital, LLC disclosed 6.7% ownership in Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share (TENX) on 31 Mar 2026."
What Changed
- Previous schedule filing date: 05 Dec 2025.
- Current filing was accepted on 07 Apr 2026, 21:34.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC | 6.7% | 1,145,100 | 0 | 1,145,100 | /s/ Neil Shahrestani | Neil Shahrestani, Sole Manager | |
| Neil Shahrestani | 6.7% | 1,145,100 | 0 | 1,145,100 | /s/ Neil Shahrestani | Neil Shahrestani |